Neither Here Nor There: How Industrial Disease Clusters Become Invisible When They Fall Between OSHA, the EPA, and Clinical Medicine

The Space Between Institutions

In Parkersburg, West Virginia, and in the communities surrounding the Washington Works DuPont facility, residents spent years reporting kidney disease, thyroid disorders, and testicular cancer before a court-mandated science panel formally linked their conditions to PFOA contamination in the local water supply. The legal and scientific resolution of that case—documented extensively in Robert Bilott's account and subsequent litigation—took decades. During that interval, affected individuals navigated a medical system that had no established diagnostic protocol for PFOA-related illness and a regulatory system in which no single agency held clear authority over the full exposure pathway.

This is not an exceptional story. It is, in fact, a representative one. Across the United States, industrial communities situated near chemical manufacturing facilities, legacy contamination sites, and agricultural operations using persistent toxic compounds share a common experience: the diseases they develop do not fit neatly into the categories that existing regulatory and clinical institutions are designed to address.

The consequences of that poor fit are not merely administrative. They are medical, legal, and deeply human.

A Jurisdictional Landscape Designed for Different Problems

The regulatory architecture governing occupational and environmental health in the United States was largely constructed in the early 1970s, when the dominant conceptual model distinguished cleanly between workplace exposures—the domain of the Occupational Safety and Health Administration—and ambient environmental contamination—the domain of the Environmental Protection Agency. The clinical dimension of that framework assumed that diseases with clear occupational or environmental etiologies would eventually find their way into standard diagnostic coding and treatment protocols through the normal mechanisms of medical research and professional consensus.

Fifty years of industrial chemistry and environmental contamination have revealed the limitations of that model. Workers at chemical facilities carry exposures home on their clothing and skin. Residents of contaminated communities experience dose patterns that blend ambient water and air contamination with secondary exposures through diet and dermal contact. The distinction between an occupational disease and an environmental disease—administratively fundamental to the US regulatory system—is frequently meaningless in the body of someone who both works at and lives near a contamination source.

OSHA's authority terminates at the facility boundary. The EPA's authority over contaminated sites is triggered by specific statutory mechanisms—Superfund designation, Clean Water Act violations, RCRA corrective action—that involve lengthy processes and high evidentiary thresholds. Neither agency has a mandate to coordinate with clinical medicine in real time, and neither is structured to recognize or respond to disease clusters that span both jurisdictional territories.

The Clinical Invisibility Problem

The medical profession's engagement with industrially generated disease clusters is constrained by a separate but related set of structural limitations. Clinical diagnosis depends on established disease classifications, recognized exposure-outcome relationships, and available biomarker tests. For emerging contaminants—PFAS compounds, novel industrial solvents, complex mixture exposures—these diagnostic prerequisites often do not yet exist at the time patients begin presenting with symptoms.

Physicians practicing in affected communities frequently encounter patients with symptom constellations that do not resolve into standard diagnostic codes. Fatigue, neurological symptoms, endocrine disruption, and atypical cancer presentations may be clinically real and causally linked to environmental exposures, but without established diagnostic criteria, they cannot be formally attributed, coded, or treated through established protocols. Insurance coverage for diagnostic workups and treatment depends on recognized diagnoses; without them, patients bear costs that the standard healthcare system will not absorb.

The result is a population that is sick, that may have a well-founded causal explanation for its illness, but that exists outside the institutional categories that would trigger clinical recognition, regulatory accountability, or financial coverage.

The Siloing of Scientific Knowledge

Occupational medicine and environmental medicine are distinct subspecialties within American clinical training, with separate board certifications, professional organizations, and research literatures. This disciplinary separation, while historically explicable, creates a knowledge gap precisely at the intersection where many industrial disease clusters are located.

Occupational medicine practitioners are trained in workplace exposure assessment and workers' compensation systems. Environmental medicine practitioners focus on community-level exposures and population health. The clinician who can fluently navigate both frameworks—and who is also familiar with the regulatory mechanisms of OSHA, the EPA, the Agency for Toxic Substances and Disease Registry, and state environmental agencies—is exceptionally rare. Most affected patients will never encounter one.

The ATSDR, which holds a statutory mandate to investigate hazardous substance exposure and its health effects, operates with a budget and staffing level that is widely regarded as inadequate for the scope of its mission. Its health consultations and public health assessments are valuable resources, but they are not substitutes for the integrated clinical and regulatory infrastructure that would be required to systematically identify and respond to industrial disease clusters in real time.

Patients as Evidence, Communities as Archives

In the absence of adequate institutional response, the documentation of industrial disease clusters has often fallen to the affected communities themselves, to investigative journalists, and to plaintiff's attorneys pursuing civil litigation. This is not a functional public health surveillance system. It is an improvised one, and it systematically disadvantages populations that lack the resources, education, or legal access to self-advocate through these channels.

The communities most heavily burdened by industrial contamination—lower-income, rural, and disproportionately communities of color—are also the communities least equipped to navigate the jurisdictional complexity that currently determines whether their health concerns receive institutional recognition. Environmental justice research has documented this pattern extensively; the regulatory system has not yet restructured itself in response.

Toward an Integrated Response Framework

Addressing this problem requires institutional redesign rather than incremental adjustment. A federal interagency coordination mechanism—with genuine authority, not merely advisory status—should be established to bridge OSHA, the EPA, the ATSDR, and the Centers for Disease Control and Prevention in cases where disease clusters span occupational and environmental exposure pathways. This mechanism should have the capacity to trigger coordinated investigation when community health surveillance data suggests an emerging cluster, without waiting for the slower machinery of Superfund designation or OSHA complaint processes.

Clinical training in occupational and environmental medicine should be restructured to address the integrated exposure realities of modern industrial communities, rather than maintaining a disciplinary separation that reflects the regulatory architecture of 1970 rather than the contamination landscape of the present.

And diagnostic coding systems, reimbursement structures, and clinical research funding should be explicitly extended to cover the investigation and treatment of exposure-related illness in populations where causation is scientifically plausible but not yet formally established—recognizing that the absence of a recognized diagnosis is frequently a product of institutional lag, not biological ambiguity.

Industrial disease clusters do not wait for jurisdictional clarity. The patients within them cannot afford to either.